About Poseida Therapeutics
Poseida Therapeutics is a company based in San Diego (United States) founded in 2015 was acquired by Roche in November 2024.. Poseida Therapeutics has raised $323.78 million across 6 funding rounds from investors including Fidelity Investments, Roche and Novartis. The company has 259 employees as of December 31, 2022. Poseida Therapeutics offers products and services including piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, and CAR-T Therapy Pipeline. Poseida Therapeutics operates in a competitive market with competitors including Celgene, Denali Therapeutics, MiRagen, Juno Therapeutics and Castle Biosciences, among others.
- Headquarter San Diego, United States
- Employees 259 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Poseida Therapeutics, Inc.
-
Annual Revenue
$64.7 M-50as on Dec 31, 2023
-
Net Profit
$-123.43 M-93as on Dec 31, 2023
-
EBITDA
$-129.5 M-116as on Dec 31, 2023
-
Total Equity Funding
$323.78 M (USD)
in 6 rounds
-
Latest Funding Round
$50 M (USD), Post-IPO
Aug 07, 2023
-
Investors
Fidelity Investments
& 14 more
-
Employee Count
259
as on Dec 31, 2022
-
Acquired by
Roche
(Nov 26, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Poseida Therapeutics
Poseida Therapeutics offers a comprehensive portfolio of products and services, including piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, and CAR-T Therapy Pipeline. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Inserts large genetic payloads into genomes for therapy development.
Enables accurate edits in cell types for cancer and disease treatments.
Develops allogeneic therapies for relapsed multiple myeloma and cancers.
Unlock access to complete
Funding Insights of Poseida Therapeutics
Poseida Therapeutics has successfully raised a total of $323.78M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $50 million completed in August 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Post-IPO — $50.0M
-
First Round
First Round
(23 Dec 2015)
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2023 | Amount | Post-IPO - Poseida Therapeutics | Valuation |
investors |
|
| Jun, 2020 | Amount | Series D - Poseida Therapeutics | Valuation | Fidelity Investments | |
| Apr, 2019 | Amount | Series C - Poseida Therapeutics | Valuation | Novartis |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Poseida Therapeutics
Poseida Therapeutics has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Roche and Novartis. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Rapha Capital Management is engaged in identifying and investing in biopharmaceutical companies.
|
Founded Year | Domain | Location | |
|
Web application services requiring JavaScript, along with potential agricultural-related offerings.
|
Founded Year | Domain | Location | |
|
PE firm investing in the US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Poseida Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Poseida Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Poseida Therapeutics Comparisons
Competitors of Poseida Therapeutics
Poseida Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Celgene, Denali Therapeutics, MiRagen, Juno Therapeutics and Castle Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for cancer and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| domain | founded_year | HQ Location |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Poseida Therapeutics
Frequently Asked Questions about Poseida Therapeutics
When was Poseida Therapeutics founded?
Poseida Therapeutics was founded in 2015.
Where is Poseida Therapeutics located?
Poseida Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Is Poseida Therapeutics a funded company?
Poseida Therapeutics is a funded company, having raised a total of $323.78M across 6 funding rounds to date. The company's 1st funding round was a Series C of $142.12M, raised on Dec 23, 2015.
How many employees does Poseida Therapeutics have?
As of Dec 31, 2022, the latest employee count at Poseida Therapeutics is 259.
What is the annual revenue of Poseida Therapeutics?
Annual revenue of Poseida Therapeutics is $64.7M as on Dec 31, 2023.
What does Poseida Therapeutics do?
Poseida Therapeutics was founded in 2015 and is based in San Diego, United States. Operations focus on the biotechnology sector, where CAR-T and gene therapy products are developed for cancer and orphan liver diseases. Genome engineering is applied to silence target genes or insert therapeutic ones. Proprietary tools such as the piggyBac DNA Modification System, CRISPR, TALEN, and Footprint-Free Gene Editing System are utilized for precise, synthetic, and virus-free modifications.
Who are the top competitors of Poseida Therapeutics?
Poseida Therapeutics's top competitors include Juno Therapeutics, Senti Biosciences and Denali Therapeutics.
What products or services does Poseida Therapeutics offer?
Poseida Therapeutics offers piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, and CAR-T Therapy Pipeline.
Who are Poseida Therapeutics's investors?
Poseida Therapeutics has 15 investors. Key investors include Fidelity Investments, Roche, Novartis, Astellas Pharma, and Perceptive Advisors.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.